Literature DB >> 11403545

Alteration in digestion and absorption of nutrients during profound acid suppression.

P Evenepoel1.   

Abstract

Gastric acid suppression therapy has for many years been the cornerstone of the treatment of peptic disease. The availability of more potent inhibitors of gastric acid secretion and the increasing demand for maintenance therapy has renewed interest in the potential side-effects of profound and/or long-lasting therapy. This chapter focuses on the potential interference of gastric acid suppression therapy with the process of the digestion and absorption of nutrients. The theoretical mechanisms by which hypochlorhydria resulting from gastric acid suppression therapy may hamper digestion and absorption are multiple and well documented. Clinical studies evaluating the effect of gastric acid suppression therapy on the assimilation of nutrients are, on the other hand, scarce and have, moreover, yielded conflicting results. The reason for the latter may be related, at least in part, to elements of study design. Data indicating overt malabsorption or clear deficiencies in patients on long-term gastric acid suppression therapy are currently lacking. Nevertheless, it seems prudent, while awaiting the results of additional long-term studies, regularly to monitor these patients, especially those with increased nutrient demand, poor intake or suboptimal stores.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403545     DOI: 10.1053/bega.2000.0197

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  9 in total

1.  Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial.

Authors:  Matthew J Wright; Rebecca R Sullivan; Erin Gaffney-Stomberg; Donna M Caseria; Kimberly O O'Brien; Deborah D Proctor; Christine A Simpson; Jane E Kerstetter; Karl L Insogna
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

2.  Proton pump inhibitor associated hypomagnasaemia - a cause for concern?

Authors:  Joe Begley; Trevor Smith; Kirsty Barnett; Paul Strike; Adnan Azim; Claire Spake; Tristan Richardson
Journal:  Br J Clin Pharmacol       Date:  2016-01-25       Impact factor: 4.335

3.  Omeprazole and refractory hypomagnesaemia.

Authors:  N Shabajee; E J Lamb; I Sturgess; R W Sumathipala
Journal:  BMJ       Date:  2008-07-10

4.  Esophageal malignancy: a growing concern.

Authors:  Jianyuan Chai; M Mazen Jamal
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

Review 5.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

6.  Omeprazole suppressed plasma magnesium level and duodenal magnesium absorption in male Sprague-Dawley rats.

Authors:  Narongrit Thongon; Jirawat Penguy; Sasikan Kulwong; Kanyanat Khongmueang; Matthana Thongma
Journal:  Pflugers Arch       Date:  2016-11-19       Impact factor: 3.657

7.  The inhibitory role of purinergic P2Y receptor on Mg2+ transport across intestinal epithelium-like Caco-2 monolayer.

Authors:  Narongrit Thongon; Siriporn Chamniansawat
Journal:  J Physiol Sci       Date:  2018-07-21       Impact factor: 2.781

8.  The roles of acid-sensing ion channel 1a and ovarian cancer G protein-coupled receptor 1 on passive Mg2+ transport across intestinal epithelium-like Caco-2 monolayers.

Authors:  Narongrit Thongon; Pattamaporn Ketkeaw; Chanin Nuekchob
Journal:  J Physiol Sci       Date:  2013-12-28       Impact factor: 2.781

Review 9.  Effect of proton pump inhibitors on dental implants: A systematic review and meta-analysis.

Authors:  Dileep Nag Vinnakota; Rekhalakshmi Kamatham
Journal:  J Indian Prosthodont Soc       Date:  2020-07-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.